COMMUNIQUÉS West-GlobeNewswire

SIGA Declares Special Cash Dividend of $0.60 Per Share
08/04/2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0. [...]
Repligen Appoints Jacob Johnson As Vice President Investor Relations
08/04/2025
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the [...]
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
08/04/2025
‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE [...]
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
08/04/2025
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
08/04/2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis [...]
EvolveImmune Therapeutics Announces Translational Research Collaboration to Evaluate Expression of Novel Tumor Target in Muscle-Invasive Bladder Cancer
08/04/2025
BRANFORD, Conn. and NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing next-generation T cell engager biotherapeutics to overcome cancer cell resistance to [...]
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
08/04/2025
EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically debilitating Preeclampsia, a serious obstetric complication, is a leading cause of near-term [...]
Microbix Provides Business Updates
08/04/2025
U.S. & Reciprocal Tariff Outcomes, Second-Half 2025 Outlook MISSISSAUGA, Ontario, April 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQB: MBXBF ) (“ Microbix® ” or the Company ”), a life [...]
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
08/04/2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
08/04/2025
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
08/04/2025
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and [...]
Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)
08/04/2025
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase Up to 128 [...]
Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development
08/04/2025
Steen Lisby, M.D., D.MSc. joins as Chief Medical Officer Jesper Valbjørn, M.Sc. joins as Senior Vice President CMC Ongoing team expansion at Myricx Bio's new facilities in London’s Canary Wharf biotech hub following [...]
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
08/04/2025
Topline Results Expected Q2 2025 PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing [...]
Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)
08/04/2025
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase Up to 128 [...]
Phonak Audéo Sphere Infinio wins Gold Edison Award for innovation in consumer solutions
08/04/2025
STÄFA, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, is proud to announce that the Phonak Audéo Sphere Infinio has been awarded the prestigious Gold Edison [...]
Nyxoah Provides Update on FDA Approvable Letter for Genio System
08/04/2025
Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – [...]
Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio
08/04/2025
Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio Prévoit de satisfaire aux exigences finales de la FDA pour obtenir l'approbation PMA complète au cours du deuxième [...]
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
08/04/2025
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data [...]

Pages